Keytruda Injection, containing Pembrolizumab 100mg, is a humanized monoclonal antibody used as an immune checkpoint inhibitor in oncology. It specifically targets the programmed death-1 (PD-1) receptor on T-cells, blocking its interaction with PD-L1 and PD-L2 ligands, thereby enhancing the immune system's ability to detect and destroy cancer cells. Keytruda is indicated for the treatment of various malignancies, including but not limited to, unresectable or metastatic melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), classical Hodgkin lymphoma, urothelial carcinoma, and microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancers. Administered via intravenous infusion, the dosing regimen varies according to the specific cancer type and patient condition. Keytruda has demonstrated efficacy in improving overall survival and progression-free survival in multiple clinical trials. Common adverse effects include fatigue, rash, pruritus, diarrhea, and immune-mediated reactions such as pneumonitis, colitis, hepatitis, endocrinopathies, and nephritis, necessitating close monitoring and prompt management. Keytruda should be used under specialist supervision with appropriate patient selection and regular assessment to optimize therapeutic outcomes while minimizing potential risks.

Dosage & How to Use